- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05923073
Studie Guselkumabu u pediatrických účastníků se středně těžkou až těžkou aktivní Crohnovou chorobou (MACARONI-23)
Fáze 3, multicentrická, randomizovaná, platformová studie inhibice p19 dráhy IL-23 ke stanovení účinnosti u dětské Crohnovy choroby
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
Přehled studie
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
- Jméno: Study Contact
- Telefonní číslo: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studijní místa
-
-
-
Nedlands, Austrálie, 6009
- Nábor
- Perth Children's Hospital
-
South Brisbane, Austrálie, 4101
- Nábor
- Mater Hospital Brisbane
-
Westmead, Austrálie, 2145
- Nábor
- The Children's Hospital at Westmead
-
-
-
-
-
Brussels, Belgie, 1090
- Nábor
- Universitair Ziekenhuis Brussel
-
Brussels, Belgie, 1200
- Nábor
- Cliniques Universitaires Saint Luc
-
Ghent, Belgie, 9000
- Nábor
- Universitair Ziekenhuis Gent
-
Leuven, Belgie, 3000
- Nábor
- UZ Leuven
-
-
-
-
-
Campinas, Brazílie, 13060-904
- Nábor
- Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
-
Curitiba, Brazílie, 80250-060
- Nábor
- Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
-
Goiânia, Brazílie, 74605-020
- Nábor
- Universidade Federal de Goias - Hospital das Clinicas da UFG
-
Porto Alegre, Brazílie, 90035-074
- Nábor
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre, Brazílie, 90035-007
- Nábor
- Hospital De Clinicas De Porto Alegre
-
Vitória, Brazílie, 29040-091
- Nábor
- Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
-
Votuporanga, Brazílie, 100000
- Nábor
- INTEGRAL Pesquisa e Ensino
-
-
-
-
-
Amiens, Francie, 80054
- Nábor
- CHU Amiens-Hopital Nord
-
Lille, Francie, 59037
- Nábor
- Hôpital Jeanne de FLANDRE, CHRU LILLE
-
Paris, Francie, 75019
- Nábor
- Hôpital Robert Debré
-
Paris, Francie, 75015
- Nábor
- Hôpital Necker - Enfants Malades
-
-
-
-
-
Rotterdam, Holandsko, 3015 GD
- Nábor
- Erasmus Medisch Centrum
-
-
-
-
-
Alessandria, Itálie, 15121
- Nábor
- A.O. Santi Antonio e Biagio e Cesare Arrigo
-
Bergamo, Itálie, 24127
- Nábor
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
Bologna, Itálie, 40124
- Nábor
- Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
-
Florence, Itálie, 50139
- Nábor
- Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
-
Milan, Itálie, 20154
- Nábor
- Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
-
Roma, Itálie, 161
- Nábor
- AOU Policlinico Umberto I
-
-
-
-
-
Beersheba, Izrael, 84101
- Nábor
- Soroka University Medical Center
-
Be’er Ya‘aqov, Izrael, 70300
- Nábor
- Shamir Medical Center Assaf Harofeh
-
Jerusalem, Izrael, 9103102
- Nábor
- Shaare Zedek Medical Center
-
Jerusalem, Izrael, 9124001
- Nábor
- Hadassah Medical Center
-
Petah Tikva, Izrael, 4920235
- Nábor
- Schneider Children's Medical Center
-
Rehovot, Izrael, 761001
- Nábor
- Kaplan Medical Center
-
-
-
-
-
Hirosaki, Japonsko, 036-8563
- Nábor
- Hirosaki University Hospital
-
Kagoshima, Japonsko, 890-8544
- Nábor
- Kagoshima University Hospital
-
Kashiwa-shi, Japonsko, 277-0871
- Nábor
- Tsujinaka Hospital Kashiwanoha
-
Kobe, Japonsko, 650 0017
- Nábor
- Kobe University Hospital
-
Saga, Japonsko, 849-8501
- Nábor
- Saga University Hospital
-
Sendai, Japonsko, 989-3126
- Nábor
- Miyagi Childrens Hospital
-
Setagaya Ku, Japonsko, 157 8535
- Nábor
- National Center for Child Health and Development
-
Tokyo, Japonsko, 113-8431
- Nábor
- Juntendo University Hospital
-
Tsu, Japonsko, 514 8507
- Nábor
- Mie University Hospital
-
Ube, Japonsko, 755-8505
- Nábor
- Yamaguchi University Hospital
-
Yokohama, Japonsko, 232-0024
- Nábor
- Yokohama City University Medical Center
-
Yokohama, Japonsko, 230-8765
- Nábor
- Saiseikai Yokohamashi Tobu Hospital
-
-
-
-
-
Busan, Jižní Korea, 48108
- Nábor
- Inje University Haeundae Paik Hospital
-
Daegu, Jižní Korea, 41404
- Nábor
- Kyungpook National University Chilgok Hospital
-
Seoul, Jižní Korea, 03080
- Nábor
- Seoul National University Hospital
-
Seoul, Jižní Korea, 06351
- Nábor
- Samsung Medical Center
-
Seoul, Jižní Korea, 120-752
- Nábor
- Severance Hospital Yonsei University Health System
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 6R8
- Nábor
- Iwk Health Centre
-
-
Ontario
-
London, Ontario, Kanada, N6A 5W9
- Nábor
- London Health Sciences Centre Victoria Hospital
-
Toronto, Ontario, Kanada, M5G 1X8
- Nábor
- Hospital For Sick Children
-
-
-
-
-
Nordbyhagen, Norsko, 1474
- Nábor
- Akershus Universitetssykehus HF
-
Oslo, Norsko, 424
- Nábor
- Oslo University Hospital
-
Tromsø, Norsko, 9038
- Nábor
- Universitetssykehuset Nord-Norge HF
-
Trondheim, Norsko, 7030
- Nábor
- St. Olavs Hospital
-
-
-
-
-
Rzeszów, Polsko, 35-302
- Nábor
- Korczowski Bartosz Gabinet Lekarski
-
Warsaw, Polsko, 04 501
- Nábor
- WIP Warsaw IBD Point Profesor Kierkus
-
Warsaw, Polsko, 04 730
- Nábor
- Instytut Pomnik Centrum Zdrowia
-
-
-
-
-
Braga, Portugalsko, 4710-243
- Nábor
- Hospital de Braga
-
Lisbon, Portugalsko, 1649-035
- Nábor
- Centro Hospitalar de Lisboa Norte Hospital Santa Maria
-
Porto, Portugalsko, 4200-319
- Nábor
- Centro Hospitalar de Sao Joao E.P.E.
-
-
-
-
-
Vienna, Rakousko, 1090
- Nábor
- AKH - Medizinische Universitat Wien
-
-
-
-
-
Glasgow, Spojené království, G51 4TF
- Nábor
- Royal Hospital for Sick Children
-
London, Spojené království, WC1N 3JH
- Nábor
- Great Ormond Street Hospital
-
Manchester, Spojené království, M13 9WL
- Nábor
- Royal Manchester Children's Hospital
-
Manchester, Spojené království, M13 9WL
- Nábor
- Nowgen Centre, Research and Innovation
-
Oxford, Spojené království, OX3 9DU
- Nábor
- John Radcliffe Hospital
-
Sheffield, Spojené království, S10 2TH
- Nábor
- Sheffield Children's Hospital
-
-
-
-
California
-
Los Angeles, California, Spojené státy, 90048
- Nábor
- Cedars Sinai Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Spojené státy, 06106
- Nábor
- Connecticut Children's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30322
- Nábor
- Emory University
-
Atlanta, Georgia, Spojené státy, 30342
- Nábor
- Children's Center for Digestive Health Care
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202-5225
- Nábor
- Riley Hospital for Children
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02115
- Nábor
- Boston Childrens Hospital
-
-
New Jersey
-
Morristown, New Jersey, Spojené státy, 07960
- Nábor
- Goryeb Children's Hospital
-
-
New York
-
New York, New York, Spojené státy, 10029
- Nábor
- Icahn School of Medicine at Mount Sinai
-
New York, New York, Spojené státy, 10032
- Nábor
- Columbia University Medical Center
-
New York, New York, Spojené státy, 10021-5663
- Nábor
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
-
-
Ohio
-
Dayton, Ohio, Spojené státy, 45404
- Nábor
- The Children's Medical Center of Dayton
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Nábor
- Children's Hospital of Philadelphia
-
-
Texas
-
Fort Worth, Texas, Spojené státy, 76104
- Nábor
- Cook Childrens Medical Center
-
-
Vermont
-
Colchester, Vermont, Spojené státy, 05446
- Nábor
- University of Vermont Medical Center
-
-
-
-
-
Córdoba, Španělsko, 14004
- Nábor
- Hosp Reina Sofia
-
Sabadell, Španělsko, 8208
- Nábor
- Corporacio Sanitari Parc Tauli
-
Valencia, Španělsko, 46026
- Nábor
- Hosp. Univ. I Politecni La Fe
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
- Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
- Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
- Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)
Exclusion Criteria:
- Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
- Participants must not have an abscess
- Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Open-label induction phase: Guselkumab Intravenously (IV)
Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
Ostatní jména:
Guselkumab will be administered intravenously.
Ostatní jména:
|
|
Experimentální: Open-label induction phase: Guselkumab Subcutaneously (SC)
Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
Ostatní jména:
Guselkumab will be administered intravenously.
Ostatní jména:
|
|
Experimentální: Double-blind maintenance phase: Guselkumab SC Dose Regimen 1
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Ostatní jména:
Guselkumab will be administered intravenously.
Ostatní jména:
|
|
Experimentální: Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Ostatní jména:
Guselkumab will be administered intravenously.
Ostatní jména:
|
|
Experimentální: Open-label maintenance phase: Guselkumab SC
Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Ostatní jména:
Guselkumab will be administered intravenously.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Participants with Clinical Remission at Week 52
Časové okno: Week 52
|
Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response at Week 52
Časové okno: Week 52
|
Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline. |
Week 52
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Participants with Clinical Response at Week 12
Časové okno: Week 12
|
Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 12
|
|
Percentage of Participants with Clinical Response at Week 52
Časové okno: Week 52
|
Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 52
|
|
Percentage of Participants with Clinical Remission at Week 12
Časové okno: Week 12
|
Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 12
|
|
Percentage of Participants with Endoscopic Remission at Week 52
Časové okno: Week 52
|
Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1. |
Week 52
|
|
Percentage of Participants with Corticosteroid-free Remission at Week 52
Časové okno: Week 52
|
Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52. |
Week 52
|
|
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
Časové okno: Weeks 12, 24, and 52
|
Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52. |
Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
Časové okno: Week 12 and/or Week 52
|
Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline. |
Week 12 and/or Week 52
|
|
Serum Concentration of Guselkumab During Induction Phase
Časové okno: From Week 0 to Week 12
|
Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method. |
From Week 0 to Week 12
|
|
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
Časové okno: At Weeks 16, 24, 36, 48 and 52
|
Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration. |
At Weeks 16, 24, 36, 48 and 52
|
|
Change from Baseline in Body Weight at Weeks 12, 24, and 52
Časové okno: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
Časové okno: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
Časové okno: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height at Weeks 12, 24, and 52
Časové okno: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
Časové okno: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
Časové okno: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
Časové okno: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical Remission
Časové okno: Week 52
|
Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response
Časové okno: Week 52
|
Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline. |
Week 52
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Časové okno: Up to Week 64
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important. |
Up to Week 64
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Clinical Trial, Janssen Research & Development, LLC
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- CR109212
- 2021-006282-37 (Číslo EudraCT)
- CNTO1959PBCRD3007 (Jiný identifikátor: Janssen Research & Development, LLC)
- 2023-504735-41-00 (Identifikátor registru: EUCT number)
- 2023 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .